CGTN
13.10.2020 08:05:04 CEST | Business Wire | Press release
Chinese President Xi Jinping on Monday arrived in south China's Guangdong Province to begin his inspection tour, his 12th domestic visit this year and his third to Guangdong since the 18th National Congress of the Communist Party of China (CPC).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201012005890/en/
"Reform and opening-up" remained the keywords during his three visits to Guangdong in 2012, 2018, 2020, respectively.
Read the original article here .
Protecting cultural legacy
During this visit, President Xi visited cultural and historical landmarks in the city of Chaozhou, including an ancient bridge, an ancient gate tower and a street lined with ancient archways, to check on the restoration and protection of cultural relics, the inheritance of intangible cultural heritage and the development of cultural and tourism resources.
The president has always insisted that the protection and exploration of cultural heritage assets must serve a country's development.
In October 2018, Xi stressed that more importance should be attached to preserving history and culture during urban planning and construction during his visit to Xiguan historical and cultural community in the Liwan District of Guangzhou City, Guangdong Province.
During this National Day and Mid-Autumn Festival holiday, the ancient township of Chaozhou received nearly 2 million tourists with a total revenue of some 890 million yuan, with its cultural charm.
The president underscored that the development of tourism should be based on protection and should not be over-commercialized when he visited the Yungang Grottoes, where he learned about historical and cultural heritage protection efforts in north China's Shanxi Province in May this year.
China's reform and opening-up paragon
President Xi also visited Chaozhou Three-Circle (Group) Co., Ltd., an electronic components and communication device manufacturer, checking out the company's indigenous innovation, production and operation.
In 2019, Guangdong's provincial GDP exceeded 10 trillion yuan (about $1.48 trillion). Under the current poverty threshold, over 1.6 million relatively poor people have reached the alleviation standard, a decisive victory in the battle against poverty.
In December 2012, President Xi visited Guangdong's Shenzhen during his first around-the-country tour after he was elected the CPC leader.
Two years ago, when China marked the 40th anniversary of reform and opening-up, he revisited the city and emphasized the need to keep promoting the process of reform and opening-up.
"I come to visit Shenzhen as it marks the 40th anniversary of reform and opening-up to tell the world that China will not stop its reform and opening-up. China will certainly deliver a bigger miracle that draws worldwide attention," he said.
Shenzhen is an important stop during his latest inspection tour to Guangdong Province.
On Wednesday morning, the president will attend a grand gathering celebrating the 40th anniversary of the establishment of the Shenzhen Special Economic Zone.
On August 26, 1980, the 15th meeting of the Standing Committee of the fifth National People's Congress, the national legislature, approved the establishment of special economic zones in Shenzhen, Zhuhai and Shantou in Guangdong Province and Xiamen in Fujian Province.
Over the past four decades, Shenzhen has been transformed from a small fishing village to a modern metropolis with a population of over 13 million.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201012005890/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)13.7.2026 14:32:00 CEST | Press release
Regulatory recognition in the United States and Europe supports the development of NB4168, a novel small molecule candidate for a rare pediatric disease with no approved treatments Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that the U.S. Food & Drug Administration (FDA) granted Rare Pediatric Disease (RPD) Designation for its proprietary lead small molecule drug candidate NB4168 for the treatment of Ataxia Telangiectasia (A-T). NB4168 is an oral small molecule therapy engineered to deliver substantially greater nicotinamide riboside (NR) exposure than conventional NR while maintaining a differentiated pharmacokinetic and safety profile. In addition, the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation (OMPD) to NB4168 for the treatment of A-T, providing regulatory recognition in the European Union and further supporting the Company'
SLB OneSubsea Awarded EPC Contract for Eni’s Baleine Phase 3 Project Offshore Côte d'Ivoire13.7.2026 14:00:00 CEST | Press release
Integrated subsea production system and local capabilities enable accelerated deepwater development Global energy technology company SLB (NYSE: SLB) announced today that its OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260712734539/en/ SLB OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. Under the contract, SLB OneSubsea will deliver complete subsea production systems (SPS) for 13 wells, reinforcing its role as a core technology and execution partner on one of the most strategically significant offshore developments currently underway in the region. The EPC scope includes subsea trees, um
HistoSonics Receives CE Mark, Unlocking Access Across Europe and Accelerating Global Commercialization of the Edison® Histotripsy Platform13.7.2026 14:00:00 CEST | Press release
HistoSonics, today announced that the company has received CE Mark approval in Europe for its Edison® System, enabling commercialization of the company’s non-invasive histotripsy technology in Europe and other markets that recognize the CE Mark. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713505048/en/ HistoSonics Edison® Histotripsy System The Edison System is a novel, non-invasive, image guided platform that is intended for the destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors. It uses the mechanical properties of focused ultrasound, called histotripsy, to liquefy and destroy unwanted tissue and tumors in a single procedure without the need for invasive procedures or radiation, and with potentially fewer side effects than traditional therapies. CE Mark approval follows an increasing number of regulatory clearances and was supported by a growing body of clinical ev
Esri Introduces ArcGIS Velocity for ArcGIS Enterprise to Power Real-Time GIS Operations13.7.2026 14:00:00 CEST | Press release
ArcGIS Velocity Brings Real-Time Data Ingestion, Analysis, and Automated Alerting to ArcGIS Enterprise Deployments Esri announces that ArcGIS Velocity is now available for ArcGIS Enterprise, enabling real-time data analytics and automated actions in self-hosted environments. This capability’s new deployment unifies real-time workflows across ArcGIS Online and ArcGIS Enterprise. This update benefits organizations across industries: public safety, transportation, logistics, and more. Esri, the global leader in location intelligence, has released for general availability ArcGIS Velocity for ArcGIS Enterprise for self-hosted deployments on Windows and Linux. This enables organizations to leverage Velocity from secure on-premises and private cloud environments. Available as software as a service (SaaS) for ArcGIS Online and now for self-hosted environments in ArcGIS Enterprise, Esri’s next-generation geospatial capability delivers real-time analytics on streaming, Internet of Things (IoT),
Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer13.7.2026 12:00:00 CEST | Press release
$85M upfront financing, along with up to $255 million upon exercise of purchase warrants, is expected to fund ROBBIN1, Agenus' registrational Phase 3 trial of neoadjuvant botensilimab and balstilimab (BOT+BAL) in microsatellite-stable (MSS) colon cancer Transaction is structured to fund Agenus through key value-inflection points, including interim topline pathologic response data and interim and final event-free survival (EFS) analyses, with proceeds to fund Agenus operations through year-end 2031, assuming full warrant exercise ROBBIN target population in MSS colon cancer represents a >$7 billion addressable annual sales opportunity in the US for which no new therapies have been approved in over 20 years2,3 To focus resources on the neoadjuvant opportunity, Agenus is discontinuing financial support for the ongoing BATTMAN Phase 3 study in late-line metastatic MSS colorectal cancer Company to host conference call and webcast today at 8:30 a.m. ET Agenus Inc. (Nasdaq: AGEN), a leader in
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
